Bio-Techne Corp (TECH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $11.44B
Last updated: Nov 17, 2026 at 11:06 AM ET
Bio-Techne Corp (TECH) Financials: Revenue, Profit and Cash Flow
Bio-Techne reported revenue of $1.22B for the fiscal year ended Jun 30, 2026, down 0.4% from the year before. That year, net income was $181.86M with a net margin of 15.0%, operating cash flow was $292.07M and free cash flow was $263.22M. The quarter ended Sep 30, 2026 had revenue of $299.71M and net income of $28.29M.
Revenue and Margins
The operating margin was 20.7% in the fiscal year ended Jun 2026. Over the 9 years to Jun 2026, revenue grew from $563.00M, a compound annual rate of 9.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $1.22B | -0.4% | 65.8% | 20.7% | 15.0% |
| Jun 2025 | $1.22B | +5.2% | 64.8% | 8.4% | 6.0% |
| Jun 2024 | $1.16B | +2.0% | 66.4% | 17.8% | 14.5% |
| Jun 2023 | $1.14B | +2.8% | 67.7% | 26.3% | 25.1% |
| Jun 2022 | $1.11B | +18.7% | 68.4% | 26.8% | 23.8% |
| Jun 2021 | $931.03M | +26.0% | 68.0% | 25.5% | 15.0% |
| Jun 2020 | $738.69M | +3.5% | 65.4% | 21.3% | 31.0% |
| Jun 2019 | $714.01M | +11.0% | 66.3% | 20.5% | 13.5% |
| Jun 2018 | $642.99M | +14.2% | 67.2% | 21.2% | 19.6% |
| Jun 2017 | $563.00M | N/A | 66.5% | 21.4% | 13.5% |
Income Statement
In the fiscal year ended Jun 2026, net income rose 147.8% from the year before. In the quarter ended Sep 2026, net income fell 25.9% from the same quarter a year earlier.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.22B | $1.16B | $1.14B | $1.11B | $931.03M | $738.69M | $714.01M | $642.99M | $563.00M |
| Cost of revenue | $415.97M | $429.36M | $389.33M | $366.89M | $349.10M | $298.18M | $255.50M | $240.51M | $210.85M | $188.46M |
| Gross profit | $799.07M | $790.27M | $769.73M | $769.82M | $756.50M | $632.85M | $483.19M | $473.49M | $432.14M | $374.54M |
| Research and development | $94.77M | $99.50M | $96.66M | $92.49M | $87.14M | $70.60M | $65.19M | $62.41M | $55.33M | $53.51M |
| Operating income | $251.89M | $102.25M | $206.69M | $298.94M | $296.59M | $237.30M | $157.42M | $146.72M | $136.18M | $120.58M |
| Net income | $181.86M | $73.40M | $168.10M | $285.44M | $263.10M | $139.59M | $229.30M | $96.07M | $126.15M | $76.09M |
| EBITDA | $343.45M | $212.99M | $309.81M | $453.70M | $412.97M | $249.40M | $377.81M | $211.32M | $200.19M | $179.05M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $299.71M | $321.19M | $311.42M | $295.88M | $286.56M | $316.96M | $316.18M | $297.03M | $289.46M | $306.10M | $303.43M | $272.60M |
| Gross profit | $196.62M | $211.39M | $208.29M | $191.28M | $188.11M | $198.81M | $214.56M | $193.89M | $183.02M | $203.35M | $204.60M | $176.59M |
| Operating income | $36.60M | $74.28M | $75.50M | $54.46M | $47.66M | -$23.86M | $38.71M | $47.42M | $39.99M | $45.82M | $67.00M | $38.00M |
| Net income | $28.29M | $54.62M | $51.05M | $38.01M | $38.19M | -$17.68M | $22.59M | $34.89M | $33.60M | $40.59M | $49.06M | $27.46M |
Balance Sheet
As of Jun 2026, cash and equivalents exceeded total debt of $200.00M by $64.71M.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.59B | $2.56B | $2.70B | $2.64B | $2.29B | $2.26B | $2.03B | $1.88B | $1.59B | $1.56B |
| Current assets | $744.40M | $608.30M | $617.42M | $621.48M | $605.56M | $510.61M | $520.92M | $412.61M | $398.37M | $348.02M |
| Cash and equivalents | $264.71M | $162.19M | $151.79M | $180.57M | $172.57M | $199.09M | $146.63M | $100.89M | $121.99M | $91.61M |
| Total liabilities | $478.50M | $639.06M | $635.02M | $672.18M | $588.79M | $691.72M | $646.40M | $718.82M | $514.14M | $608.59M |
| Short-term debt | $0 | $14.10M | $12.92M | $3.50M | $12.50M | $16.50M | $18.44M | $15.90M | $0 | $65.10M |
| Long-term debt | $200.00M | $346.00M | $319.00M | $350.00M | $243.41M | $328.83M | $344.24M | $492.66M | $339.00M | $343.77M |
| Shareholder equity | $2.11B | $1.92B | $2.07B | $1.97B | $1.70B | $1.56B | $1.38B | $1.17B | $1.08B | $949.63M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.64B | $2.59B | $2.55B | $2.52B | $2.53B | $2.56B | $2.64B | $2.67B | $2.74B | $2.70B | $2.72B | $2.73B |
| Total liabilities | $471.13M | $478.50M | $465.30M | $511.71M | $560.33M | $639.06M | $626.23M | $591.93M | $597.37M | $635.02M | $706.79M | $767.19M |
| Cash and equivalents | $350.04M | $264.71M | $209.82M | $172.88M | $144.96M | $162.19M | $140.67M | $177.55M | $187.54M | $151.79M | $139.91M | $130.13M |
| Shareholder equity | $2.17B | $2.11B | $2.09B | $2.01B | $1.97B | $1.92B | $2.02B | $2.08B | $2.14B | $2.07B | $2.01B | $1.96B |
Cash Flow
In the fiscal year ended Jun 2026, free cash flow was 90.1% of operating cash flow. Dividends and share repurchases together came to 34.8% of it.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $292.07M | $287.56M | $298.98M | $254.39M | $325.27M | $352.16M | $205.22M | $181.62M | $170.37M | $143.72M |
| Capital expenditures | $28.85M | $31.01M | $62.88M | $38.24M | $44.91M | $44.30M | $51.74M | $25.41M | $20.93M | $15.18M |
| Free cash flow | $263.22M | $256.55M | $236.10M | $216.15M | $280.36M | $307.86M | $153.47M | $156.21M | $149.43M | $128.54M |
| Dividends paid | $49.92M | $50.39M | $50.42M | $50.28M | $50.19M | $49.62M | $48.90M | $48.36M | $47.97M | $47.33M |
| Share repurchases | $41.67M | $275.73M | $80.04M | $19.56M | $160.95M | $43.18M | $50.11M | $15.40M | $0 | $0 |
| Investing cash flow | -$18.19M | -$35.18M | -$203.03M | -$265.65M | -$96.85M | -$243.52M | $27.09M | -$336.80M | -$38.71M | -$305.95M |
| Financing cash flow | -$169.11M | -$253.91M | -$122.40M | $22.62M | -$242.85M | -$62.55M | -$183.80M | $134.38M | -$99.19M | $189.11M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $73.11M | $95.42M | $86.66M | $82.41M | $27.59M | $98.20M | $41.12M | $84.35M | $63.89M | $75.50M | $80.99M | $83.12M |
| Capital expenditures | $5.92M | $8.48M | $9.09M | $5.92M | $5.36M | $4.89M | $10.12M | $6.82M | $9.17M | $17.98M | $16.44M | $14.86M |
| Free cash flow | $67.20M | $86.94M | $77.58M | $76.49M | $22.22M | $93.31M | $31.00M | $77.53M | $54.72M | $57.52M | $64.55M | $68.25M |
Frequently Asked Questions About TECH
What is Bio-Techne's annual revenue?
Bio-Techne reported revenue of $1.22B for the fiscal year ended Jun 30, 2026.
How fast is Bio-Techne's revenue growing?
Revenue was down 0.4% for the fiscal year ended Jun 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 2.2%.
Is Bio-Techne profitable?
Yes. Bio-Techne reported net income of $181.86M for the fiscal year ended Jun 30, 2026, with a net margin of 15.0%.
How much free cash flow does TECH generate?
For the fiscal year ended Jun 30, 2026, operating cash flow of $292.07M minus capital expenditures of $28.85M produced free cash flow of $263.22M.
How much debt does Bio-Techne have?
The balance sheet dated Jun 30, 2026 reported long-term debt of $200.00M, short-term debt of $0 and cash and equivalents of $264.71M.
TECH pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors